Innovating Pain Management: Autonomix Medical's Groundbreaking Technology

Autonomix Medical, Inc. (NASDAQ: AMIX) is a pioneering medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The company's first-in-class platform technology includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. This advancement has the potential to transform various disease categories, from chronic pain management to hypertension and cardiology.

Autonomix is currently developing its technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that can cause debilitating pain and requires an effective solution. In a recent proof-of-concept human clinical trial, the company demonstrated promising preliminary results. The trial, which included 15 patients, showed that 79% of patients responded to the treatment, with a mean reduction of 4.96 points on the VAS pain scale at 7 days post-procedure. Notably, all responding patients went to zero opioid use after their 24-hour post-procedure follow-up visit, and none needed opioid dose increase. Additionally, responding patients reported a mean 66% improvement in overall health status at 7 days post-procedure.



Autonomix's innovative platform offers several advantages over existing treatments. By enabling transvascular diagnosis and treatment of diseases involving the peripheral nervous system, the technology allows for targeted interventions without the need for invasive surgeries. This precision targeted approach significantly reduces the risk of collateral damage to surrounding tissues and organs. Moreover, Autonomix's technology can sense and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies, enabling more accurate and effective nerve ablation. Lastly, Autonomix's platform can address a wide range of indications, making it a versatile solution for various nerve-related disorders.

The successful completion of the 15-patient trial has paved the way for further development and clinical studies. The company remains focused on its pancreatic cancer pain development program and is on track to complete enrollment in its ongoing proof-of-concept (PoC) human clinical trial by calendar year-end. As Autonomix continues to advance its technology, investors can expect further data-driven insights into the efficacy and safety of its innovative approach to pain management and other nerve-related disorders.



In conclusion, Autonomix Medical, Inc. is at the forefront of neurostimulation technology, offering a novel approach to pain management and other nerve-related disorders. The company's first-in-class platform technology enables precision-guided, transvascular diagnosis and treatment of diseases involving the peripheral nervous system. With promising preliminary results from its clinical trial and a wide range of potential indications, Autonomix has the potential to revolutionize the way diseases involving the nervous system are diagnosed and treated. As the company continues to advance its technology and expand its indications, investors can expect exciting developments in the realm of innovative medical devices.